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Abstract 
Manganese oxide (MnO) nanocubes were fabricated and their surface were modified by ligand encapsulation or 
ligand exchange, to render them water‑soluble. And then, MnO formed the hollow structure by etching using acidic 
solution (phthalate buffer, pH 4.0). Depending on the ligand of the MnO surface, it increases the interaction between 
MnO and water molecules. Also, the hollow structure of MnO, as well as the ligand, can greatly enhance the acces‑
sibility of water molecules to metal ions by surface area‑to‑volume ratio. These factors provide high R1 relaxation, 
leading to strong T1 MRI signal. We have confirmed T1‑weighted MR contrast effect using 4‑kinds of MnO nanocubes 
(MnOEn, MnOEnHo, MnOEx and MnOExHo). They showed enough a MR contrast effect and biocompatibility. Espe‑
cially, among them, MnOExHo exhibited high T1 relaxivity (r1) (6.02 mM−1 s−1), even about 1.5 times higher sensitivity 
than commercial T1 MR contrast agents. In vitro/in vivo studies have shown that MnOExHo provides highly sensitive 
T1‑weighted MR imaging, thereby improving diagnostic visibility at the disease site.
Keywords: Hollow nanostructure, Ligand encapsulation and exchange, Manganese oxide nanocube, MR imaging, T1 
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1 Introduction
Magnetic resonance imaging (MRI) is not only able to 
provide anatomical images with significant spatial resolu-
tion and depth, but also attracts more and more attention 
due to its non-radioactive and non-invasive properties 
[1–5]. Two types of contrast agents are used for MRI 
scans. Negative contrast or T2-weighted magnetic reso-
nance (MR) images are generated by superparamagnetic 
iron oxide nanoparticles, reducing the spin–spin relaxa-
tion time of the water [6–9]. Positive contrast or proton 
MR images are generated by T1-based contrast agents 
such as manganese oxide (MnO) nanoparticles or gado-
linium  (Gd3+) to reduce spin–lattice relaxation time of 
nearby water molecules, resulting in the brightening of 
the voxel [10–13]. Tremendous research has led to sig-
nificant advancements in technology and the controlled 
construction of nanomaterials. Chemical, physical, or 
biological methods can be used for the synthesis of nano-
materials, allowing for accurate control of their shape, 
composition, size and surface characteristics [14–18]. 
These parameters can be easily tailored to tune the physi-
cal and chemical properties of nanomaterials. Through 
decades of research, a diverse approach has been devel-
oped for the synthesis of MnO nanoparticles [10, 19–27]. 
Despite the increased interest, T1-based MRI is relatively 
limited due to ratiometric complications and low signal 
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intensities. In addition, to influence the relaxation time, 
T1 contrast agent needs to interact directly with the sur-
rounding water protons [28–30]. In case of nanospheres, 
only ions that are exposed on the surface are effective. 
Reducing the particle size on the basis of the same con-
centration of ions that make up the particle can provide 
a larger surface area. Additionally, by transforming the 
particles to the hollow structures, the particle surface 
percentage can be increased, which can, in turn, provide 
higher relaxivity. Hollow particles can offer high specific 
area and have excellent penetration and permeability. The 
volumetric capacity is quite high, which allows access to 
more water molecules to improve MR contrast [31, 32]. 
In addition, ligand exchange can make the surface hydro-
philic, which further enhances the contrast compared to 
bilayer coated particles. Hydrophobic inner coating can 
hinder moisture penetration and reduce spin effect [33–
36]. Until now, several hollow MnO-based nanoparticles 
have been developed, including MnO particles loaded 
with iron oxide nanoparticles or drug molecules [37–39]. 
Despite this development, hollow MnO particles have 
not been optimized for low relaxation and maximum 
contrast enhancement.
Herein, we report on the development of four 
water-soluble MnO nanocubes, namely (1) MnOEn: 
poly(ethylene glycol) phospholipid-encapsulated MnO 
nanocubes (2) MnOEnHO: hollow poly (ethylene glycol) 
phospholipid-encapsulated MnO nanocubes (3) MnOEx: 
ligand (polyacrylic acid)-exchanged MnO nanocubes, 
and (4) MnOExHo: hollow ligand (polyacrylic acid)-
exchanged MnO nanocubes. The ability to tailor MnO 
nanocubes for maximum contrast enhancement along 
with changes in their chemical and physical structure, 
MR properties, and biocompatibility has been demon-
strated (Fig. 1).
2  Results and discussion
2.1  Synthesis and modification of MnO nanocubes
Monodisperse MnO nanocubes were synthesized by the 
thermal decomposition of manganese oleate complexes 
at a high temperature in a nonpolar organic solvent. The 
TEM images of the as-prepared MnO nanocubes show 
that the nanoparticles exhibit uniform size of 70  nm 
(length, l) and 65 nm (width, w) with high monodispersity 
(Fig. 2b). Following the synthesis of the MnO nanocubes, 
surface modification was performed to transfer MnO 
into the aqueous phase (D.W.). The outer surface of the 
MnO nanocubes was modified either by surface encap-
sulation (MnOEn) using poly(ethylene glycol) (PEG)-
phospholipid (Fig.  2c) or by ligand exchange (MnOEx) 
using polyacrylic acid (PAA) (Fig. 2e). In both cases, the 
nanoparticles were well-dispersed in the aqueous phase. 
Next, etching using an acidic solution (phthalate buffer, 
pH 4.0) was performed to form hollow MnO (MnOEnHo 
and MnOExHo) nanocubes (Fig.  2d, f ). When the area 
around the MnO particles was acidic condition, the sur-
face part was etched. In particular, it was known that in 
the phthalate buffer (pH = 4.0), the center of the parti-
cle was made hollow structure as the surroundings were 
etched [30, 31]. During etching, the particles formed 
a clear and light-brown solution, and the carved MnO 
core adhered itself to the magnetic bar. The entire pro-
cess was simple and highly reproducible. The as-prepared 
MnO, MnOEn, MnOEnHo, MnOEx, and MnOExHo 
Fig. 1 Schematic of the synthetic procedure of MnOEn, MnOEnHo, MnOEx and MnOExHo using MnO
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were characterized by HR-TEM (Fig.  2), which clearly 
shows that the synthesized nanoparticles retained the 
size and shape uniformity of the original MnO nano-
cubes. Furthermore, their successful phase transfer from 
an oil phase (hexane) to an aqueous solution (D.W.) was 
observed after surface ligand encapsulation or exchange 
from oleic acid to lipid or PAA, respectively (Fig. 2a).
Fig. 2 a Photos of the dispersibility of MnO in oil phase (hexane) and each MnO nanocube in aqueous phase (D.W.). TEM images of b MnO, c 
MnOEn, d MnOEnHo, e MnOEx, and f MnOExHo (scale bar: 50 nm)
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2.2  Characterization of MnO nanocubes
The size distribution of particles and their dispersion 
stability in the aqueous solution were measured using 
dynamic light scattering (DLS) analysis and zeta potential 
analyzer. DLS analysis defines the particles as spherical 
and measures the hydrodynamic diameter of the particles 
dispersed in the aqueous phase. Therefore, it is not accu-
rate because it is in the form of a cube but its approxi-
mate hydrodynamic size and dispersibility in aqueous 
phase can be confirmed. There size were 99.1 ± 9.2  nm 
(MnOEn), 106.9 ± 8.9  nm (MnOEnHo), 92.2 ± 9.0  nm 
(MnOEx), and 109.7 ± 4.6 nm (MnOExHo), respectively 
(Fig.  3a). Especially, they exhibited low standard devia-
tion, indicating that each particle were stably dispersed 
in the aqueous phase without aggregation. In addition, it 
was known that the surface charges were influenced by 
surface coating materials [40–44]. Therefore, the positive 
charges of MnOEn and MnOEnHo were attributed to the 
Fig. 3 a Size distributions histogram using dynamic light scattering analysis, b Zeta potential values, c X‑ray diffraction patterns, and d magnetic 
hysteresis loop analyzed using vibrating sample magnetometer [MnOEn (blue line), MnOEnHo (red line), MnOEx (green line), MnOExHo (yellow 
line), and MnO (black line)]
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presence of amine groups in the lipid. Meanwhile, the 
negative charges of MnOEx and MnOExHo were attrib-
uted to the presence of carboxyl groups of PAA on their 
surfaces (Fig. 3b).
The X-ray diffraction (XRD) results of MnO, MnOEn, 
MnOEnHo, MnOEx, and MnOExHo indicate that the 
crystalline peaks match the series of Bragg reflections 
corresponding to the standard, and the phase pure cubic 
rock salt structure of MnO (a = 4.442 Å) was maintained 
even after ligand exchange and surface modification 
(Fig.  3c). The field-dependent magnetization curves for 
MnOEn, MnOEnHo, MnOEx, and MnOExHo showed 
similar magnetization values (1.82–2.41 emu/mg) in 
an external magnetic field of 1.5 T with no remanence 
coercivity at zero field, indicating that these particles 
exhibited paramagnetic properties at room temperature 
(Fig. 3d). Thermogravimetric analysis (TGA) was used to 
confirm the ratio of surface modification on the surface 
of each MnO nanocube (Fig.  4). MnOEn contains 23.2 
wt% of organic layer composed of oleic acid and PEG-
phopholipid and 76.7 wt% of inorganic materials (MnO). 
After MnO etching, MnOEnHo was stably formed the 
hollow structure in MnO, so the ratio of organic layer in 
MnOEnHo increased to 32.4 wt% and the inorganic ratio 
decreased to 67.6 wt% (Fig. 4a). Likewise, MnOExHo had 
a less MnO ratio than MnOEx, indicating that the hollow 
structured nanocube was well formed (inorganic ratio in 
MnOEx: 84.8 wt% and inorganic ratio in MnOExHo: 83.1 
wt%) (Fig. 4b).
In addition, we evaluated the feasibility of nanoparti-
cles as T1 MRI agents and confirmed their MR contrast 
effects. The T1-weighted MR images acquired on a 3.0 T 
MRI scanner reveal the concentration-dependent signal 
enhancement, which validates the advantage of hollow 
MnO nanocubes over solid MnO nanocubes. As indi-
cated in Fig.  5a, the MnOEn, MnOEnHo, MnOEx, and 
MnOExHo at the same concentration of 1 mM (based on 
the Mn concentration measured by inductively coupled 
plasma atomic emission spectroscopy) clearly showed 
bright signal enhancement. When we measured their MR 
signal intensities in an aqueous phase under various con-
centration at room temperature, the T-1 weighted MR 
images showed an increasingly stronger bright image as 
the concentration increased. Among them, MnOExHo 
showed the strong T1 MR signals, as the Mn concen-
tration increased, and corresponding the longitudinal 
relaxivity (r1) was 6.02 mM−1  s−1. It was 6.02, 1.61, and 
1.14 times those of MnOEn (1.00 mM−1 s−1), MnOEnHo 
(3.74 mM−1  s−1), and MnOEx (5.28 mM−1  s−1), respec-
tively. As well, T1 relaxivity (r1) of MnOExHo was 
higher (approximately 1.16–1.47-fold) that that of com-
mercial T1 MRI contrast media  (Magnevist®: 4.1 mM−1 
 s−1 and  Gadovist®: 5.2  mM−1  s−1). These enhance-
ments in MnOExHo and MnOEnHo can be attributed 
to the increased volumetric capacity to access water 
molecules, which leads to an enhanced spin effect. The 
greater signal enhancement of MnOExHo, when com-
pared to MnOEnHo, could be due to the bilayer effect 
of MnOEnHo, that is, the presence of a hydropho-
bic layer decreases the accessibility of water molecules 
to the metal ions. Furthermore, the T2-weighted MR 
images were obtained for each MnO nanocube con-
centration (Fig.  5b). The transversal relaxivity (r2) of 
MnOExHo, calculated on the basis of the Mn ion con-
centration, was 9.34 mM−1  s−1, which was 1.19, 1.12, and 
1.08 times those of MnOEn (7.82 mM−1  s−1), MnOEnHo 
Fig. 4 TGA analysis of a MnO (black line), MnOEn (blue line), MnOEnHo (red line), oleic acid (cyan line) and lipid (light violet line), b MnO (black line), 
MnOEx (green line), MnOExHo (yellow line) and polyacrylic acid (PAA) (light blue line)
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(8.34 mM−1  s−1), and MnOEx (8.64 mM−1  s−1), respec-
tively (Fig.  5b). It has been reported that the ideal T1 
MRI contrast agent should have an r2/r1 ratio close to 1 
(one) [45, 46]. As shown in Fig. 5c, MnOExHo had high 
r1 value (6.02 mM−1  s−1) and r2/r1 value close to 1 (1.55), 
confirming the sufficient ability of MnOExHo as a T1 
MRI contrast agent.
2.3  Cell viability of MnO nanocubes
The cellular cytotoxicity of the each MnO nanocubes 
was assessed in a gastric cancer cell line, SNU-484, using 
an MTT assay (3-(4,5-dimethylthiazol-2-y1)-2,5-diphe-
nyltetrazolium bromide). As shown in Fig. 6, more than 
80% of the cells survived at a high concentration of 1 mM 
all MnO nanocubes, indicating that these nanocubes 
showed biocompatibility even at high concentrations of 
MnO nanocubes.
2.4  Cellular MR imaging using MnOExHo
Additionally, MnOExHo having the highest T1 MRI 
sensitivity was treated with SNU-484 cells to evaluate 
Fig. 5 a T1‑weighted MR images and b T2‑weighted MR images depending on the concentration of each particle and plots of each relaxation (1/
T1 and 1/T2) against Mn concentration. c Calculation of R1 relaxivity (r1), R2 relaxivity (r2) and r2/r1 [MnOEn (blue line), MnOEnHo (red line), MnOEx 
(green line), and MnOExHo (yellow line)]
Page 7 of 11Kukreja et al. Nano Convergence            (2020) 7:16  
its diagnostic ability as T1 MRI contrast agent. The 
SNU-484 cells treated with MnOExHo at concentra-
tions of 0.2 and 1  mM showed significant MR con-
trast effects. MnOExHo-treated cells definitely showed 
bright images compared with the untreated cells. The 
T1-weighted MR images gradually changed from dark 
black to bright white as the concentration of treated 
MnOExHo in the cells increases (Fig.  7a). MR signal 
intensity (ΔR1/R1NT, ΔR1 = R1 −  R1NT) was higher in 
treated cells than in non-treated cell (NT) (MnOExHo 
(0.2  mM)-treated cells: 71%, MnOExHo (1.0  mM)-
treated cells: 134%) (Fig. 7a). In the TEM images of the 
MnOExHo-treated cells, furthermore, many black dots 
were observed, indicating the entry of the MnOExHo 
nanocubes into the SNU-484 cells (Fig. 7b).
2.5  In vivo MR imaging of MnOExHo
We next performed in vivo MRI using MnOExHo to eval-
uate their diagnostic ability as a T1 MRI contrast agent 
in tumor-bearing mice. Tumor-bearing mice with gastric 
cancer were prepared, and MnOExHo (200 μgMn/μl) 
were injected into mouse tail vein (intravenous injection). 
We monitored MR imaging at different time intervals 
(pre-injection, immediately following injection, and 1, 2, 
4, and 48 h post-injection) (Fig. 8), before and after MnO-
ExHo injection. As soon as MnOExHo injection, tumor 
region [red dashed line region) appeared bright in the T1 
MR images with high MR signal intensity, compared with 
before injection (Fig.  8a)]. To obtain quantitative and 
dependable results for signal intensity measurements, we 
analyzed the MR signal in the tumor by drawing ROIs of 
whole tumor volumes on both the T1-weighted images 
(Fig.  8b). The T1 signal intensity gradually increased 
Fig. 6 Cell viability of SNU‑484 cells incubated with a MnOEn (blue), b MnOEnHo (red), c MnOEx (green) and d MnOExHo (yellow) at various 
concentrations for 24 h at 37 °C
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after administration of MnOExHo, and showed the high-
est signal enhancement of 144.3% (1.44 times) 1  h after 
injection. Especially, MR images at 1–2 h after injection 
showed the brightest images at the tumor region, and 
MR signal intensities were also increased with a similar 
trend to MR images (Fig. 8). This is because MnOExHo 
circulated in the blood stream and gradually accumu-
lated in tumor tissues by the enhanced permeability and 
retention (EPR) effect. After 48 h, no bright image of the 
tumor area was seen, and the increased MR signal was 
reduced as before particle injection (pre-injection). We 
judged that MnOExHo accumulated in tumor within 
1–2 h and then excreted out of the tumor up to 48 h.
3  Conclusions
In this study, we developed various types of MnO nano-
cubes for using effective T1-weighted MRI agents. The 
as-synthesized MnO nanocubes were rendered water-
soluble by ligand exchange and ligand encapsulation. 
Moreover, treatment with the acidic solution (phthalate 
buffer) was used to form hollow MnO nanocubes. Fur-
thermore, it was confirmed that the hollow structure 
and the surface ligand exchange of the MnO nanocubes 
allow greater access of Mn ions to the water molecules, 
thus exhibiting a maximum enhancement of longitudinal 
relaxation time and inducing strong T1 MR signal. There-
fore, this study suggest that MnOExHo could be used as 
effective T1 contrast agents for biomedical research.
4  Experimental methods
4.1  Materials
Diethylene glycol (DEG), manganese (II) formate 
[Mn(COOH)2], tri-n-octylamine (TOA), oleic acid 
(OA), and polyacrylic acid (PAA) were purchased 
from Sigma-Aldrich. Ethanol, chloroform and a phtha-
late buffer (pH 4.0) were procured from Samchun 
Chemical. 1,2-distearoyl-sn-glycero-3-phosphoetha-
nolamine-N-[methoxy(aminoethylene glycol)-2000] 
Fig. 7 a T1‑weighted MR images and relative signal intensity graphs of SNU‑484 cells incubated with MnOExHo (ΔR1 = R1 −  R1NT, NT: no 
treatment), b TEM images of SNU‑484 cells treated with MnOExHo (scale bar: 500 nm, inset scale bar: 2 μm)
Fig. 8 a In vivo T1‑weighted MR images and b their relative T1 signal intensity (%) (red dashed line region) of orthotopic gastric cancer mice model 
after intravenous injection of MnOExHo (200 μg Mn per mouse) at different time points (pre‑injection, immediately after, and 1, 2, 4, and 48 h 
post‑injection)
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(PEG-Phospholipid) (mPEG-2000 PE, Avanti Polar 
Lipids, Inc.) was used as-purchased without any puri-
fication. All other reagents purchased from commercial 
sources were used as-obtained without further purifica-
tion. Furthermore, ultrapure deionized water was used 
for all the synthesis processes.
4.2  Synthesis of MnO nanocubes
Mn(COOH)2 (1 mmol) was added to a mixture contain-
ing 3  mmol of TOA and 3  mmol of OA. The resulting 
mixture was heated to 130 °C under vacuum until all the 
moisture was removed. First, the solution was heated 
to 280  °C for 1 h and then refluxed at 330  °C, where its 
color changed from brownish red to green. Then, it was 
left for 1  h under  N2 flow to yield uniform MnO nano-
cubes. Finally, it was allowed to cool at room temperature 
(25 °C). The resulting particles were precipitated by add-
ing ethanol and centrifuged at 6000 rpm for 10 min; they 
were then washed with chloroform and ethanol twice and 
finally, dispersed in chloroform.
4.3  Fabrication of MnOEn and MnOEx
A total of 10 mg of organic dispersible MnO nanocubes 
was added to 10  mL of chloroform solution containing 
50 mg of PEG-phospholipid in a ratio of 5:1. After evapo-
rating the solvent, the solution was incubated at 80 °C in 
vacuum for 1 h. The addition of 20 mL of water resulted 
in a clear, dark-brown suspension. Next, centrifugation 
was performed at 21,000  rpm for 30  min, and the par-
ticles were ultimately dissolved in the aqueous phase. 
Ligand exchange reactions were performed to modify the 
surface of the hydrophobic oleate-capped MnO nano-
cubes. A solution containing 20 mL of DEG and 200 mg 
of PAA was heated to 200 °C under vacuum for 1 h with 
magnetic stirring, followed by refluxing under  N2 for 2 h 
at the same temperature. Then, a solution of 40 mg MnO 
in 4  mL of hexane was immediately added to the flask, 
and the resulting mixture was maintained at 200  °C for 
another 6 h. After cooling the solution to room tempera-
ture, the resulting nanocubes were precipitated by add-
ing ethanol and collected by centrifugation. The particles 
were ultimately dissolved in the aqueous phase.
4.4  Preparation of hollow‑typed MnO nanocubes 
(MnOEnHo and MnOExHo)
A total of 10 mg of the synthesized MnOEn and MnOEx 
nanocubes was dispersed into 20 mL of phthalate buffer 
at pH 4.0 and stirred for 12  h to carve away the MnO 
core. The resulting particles (MnOEnHo and MnOExHo) 
were obtained by centrifugation and resuspension in dis-
tilled water.
4.5  Cell cytotoxicity assay
SNU-484 cells from a gastric cancer cell line were 
obtained from the Korean Cell Line Bank (Seoul, Korea). 
The cells were maintained in RPMI medium supple-
mented with 10% FBS and 1% antibiotic–antimitotic 
at 37  °C with 5%  CO2. The in  vitro cytotoxicity of each 
MnO nanocube was assessed by the standard MTT assay. 
The SNU-484 cells were seeded in a 96-well plate at a 
density of  104 cells per well, and cultured in 5%  CO2 at 
37 °C for 24 h. Then, various concentrations of each MnO 
nanocube were added to the medium and the cells were 
further incubated for 24  h. Afterward, the media was 
removed and MTT1 solution was added; the cells were 
incubated for another 4 h. The medium was then replaced 
with MTT2 solution, and, after 24 h, measurements were 
recorded at an absorbance–wavelength of 575  nm and 
a reference wavelength of 650  nm, using a multimode 
microplate reader. The cell viabilities were determined by 
calculating the ratio of the intensity of purple formazan 
formed in the viable cells treated with the nanocubes to 
the intensity of that in the untreated control cells.
4.6  Cellular internalization of MnOExHo nanocubes
First, 2 × 107 SNU-484 cells suspended in PBS (1 mL) was 
incubated with MnOEnHo (14 μg and 70 μg, respectively) 
and additionally incubated for 4  h at 37  °C. MnOEnHo 
incubated SNU-484 cells were e-suspended in 200 μL 
of 4% paraformaldehyde for MR imaging analysis. Their 
relaxivity coefficient  (mM−1  s−1) was equal to the ratio 
of R1 (1/T1,  s−1) and the concentration of Mn. As well, 
the cellular internalization of the MnOExHo nanocubes 
was confirmed by TEM (JEOL-1011). SNU-484 cells  (106 
cells/well) were seeded onto six-well plates overnight and 
then incubated with the MnOExHo nanocubes (1 mM in 
medium) in a 5%  CO2 atmosphere at 37  °C. After incu-
bation for 8 h, the SNU-484 cells treated with the MnO-
ExHo nanocubes were washed thrice with a phosphate 
buffered solution (pH 7.4, 10 mM), trypsinized (0.5 mL), 
and subsequently, harvested. Then, following collec-
tion, the cells were fixed using the standard fixation and 
embedding protocol for resin-section transmission elec-
tron microscopy (TEM) and sectioned using a LEICA 
Ultracut UCT ultra-microtome (Leica Microsystems, 
Austria).
4.7  In vivo model procedure
All animal experiments were conducted with the 
approval of the Association for Assessment and Accredi-
tation of Laboratory Animal Care International. To 
establish an orthotopic mouse model of gastric cancer, 
SNU-484 cells (1.0 × 107 cells) were implanted into the 
fundic glands of the stomachs of male mice (6-week-old 
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balb/c-nude mice). Then, MRI was performed on five 
mice, 4 weeks after the tumor cell transplantation. When 
the tumor size reached approximately 500  mm3, water-
soluble MnOExHo (200  μg) was injected intravenously 
into the tail vein.
4.8  MR imaging procedure
We performed MR imaging experiment of MnO nano-
cubes solution with a 3.0 T clinical MRI scanner with 
a micro-47 surface coil (Intera; Philips Medical Sys-
tems, Best, the Netherlands). The R1 relaxivity of vari-
ous concentrations of MnO nanocubes was measured 
by the Carr–Purcell–Meiboom–Gill (CPMG) sequence 
at room temperature with the following parameters: 
echo time (TE) = 60 ms, repetition time (TR) = 4000 ms, 
slice thickness = 2.0  mm, number of acquisitions = 1, 
and point resolution = 234 × 234  μm2. The relaxivity 
values of R1 were calculated by a series of T1 values, 
when plotted as 1/T1 versus [Mn]. The relaxivity coef-
ficient  (mM−1  s−1) was equal to the ratio of R1 (1/T1, 
 s−1) and the nanoparticle concentration. In vitro/in vivo 
MRI experiments were performed using a 3.0 T clinical 
MRI instrument equipped with a micro-47 surface coil 
(Intera; Philips Medical Systems, Best, Netherlands). 
To acquire cellular T1-weighted MR images, following 
parameters were adopted: resolution = 234 × 234  mm, 
section thickness = 3.0  mm, TE = 18  ms, TR = 625  ms, 
and number of acquisitions = 2. For T1-weighted MR 
images of the nude mice, the following parameters were 
adopted: resolution = 234 × 234  mm, section thick-
ness = 2.0  mm, TE = 60  ms, TR = 4000  ms, and number 
of acquisitions = 1.
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